Kopečková K - Search Results

1

Cytochrome P450 and flavin-containing monooxygenase enzymes are responsible for differential oxidation of the anti-thyroid-cancer drug vandetanib by human and rat hepatic microsomal systems.

Indra R, Pompach P, Vavrová K, Jáklová K, Heger Z, Adam V, Eckschlager T, Kopečková K, Arlt VM, Stiborová M. Indra R, et al. Among authors: kopeckova k. Environ Toxicol Pharmacol. 2020 Feb;74:103310. doi: 10.1016/j.etap.2019.103310. Epub 2019 Dec 3. Environ Toxicol Pharmacol. 2020. PMID: 31837525

2

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.

Belada D, Kopeckova K, Bergua Burgues JM, Stevens D, André M, Persona EP, Pichler P, Staber PB, Trneny M, Duell J, Waldron-Lynch M, Wagner S, Mukhopadhyay A, Dirnberger-Hertweck M, Burke JM, Nowakowski GS. Belada D, et al. Among authors: kopeckova k. Blood. 2023 Oct 19;142(16):1348-1358. doi: 10.1182/blood.2023020637. Blood. 2023. PMID: 37369099 Free PMC article. Clinical Trial.

3

Is rare cancer care organized at national health system level? Multiple case study in six EU countries.

Prades J, Trama A, Casali PG, Emile JF, Gaspar N, Janavicius R, Jančiauskienė R, Karjalainen S, Kopeckova K, Pylkkänen L, Svoboda M, Borras JM. Prades J, et al. Among authors: kopeckova k. Eur J Public Health. 2022 Nov 29;32(6):852-857. doi: 10.1093/eurpub/ckac166. Eur J Public Health. 2022. PMID: 36374643 Free PMC article.

4

Effectiveness of human cytochrome P450 3A4 present in liposomal and microsomal nanoparticles in formation of covalent DNA adducts by ellipticine.

Sulc M, Mrizova I, Cerna T, Frei E, Eckschlager T, Adam V, Kopeckova K, Stiborova M. Sulc M, et al. Among authors: kopeckova k. Neuro Endocrinol Lett. 2016 Dec 18;37(Suppl1):95-102. Neuro Endocrinol Lett. 2016. PMID: 28263536

5

Cytochrome b₅ plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine.

Stiborová M, Indra R, Frei E, Kopečková K, Schmeiser HH, Eckschlager T, Adam V, Heger Z, Arlt VM, Martínek V. Stiborová M, et al. Among authors: kopeckova k. Monatsh Chem. 2017;148(11):1983-1991. doi: 10.1007/s00706-017-1986-9. Epub 2017 Jul 4. Monatsh Chem. 2017. PMID: 29104319 Free PMC article.

6

Paclitaxel-Loaded Polylactide/Polyethylene Glycol Fibers with Long-Term Antitumor Activity as a Potential Drug Carrier for Local Chemotherapy.

Plch J, Venclikova K, Janouskova O, Hrabeta J, Eckschlager T, Kopeckova K, Hampejsova Z, Bosakova Z, Sirc J, Hobzova R. Plch J, et al. Among authors: kopeckova k. Macromol Biosci. 2018 Jun;18(6):e1800011. doi: 10.1002/mabi.201800011. Epub 2018 Apr 24. Macromol Biosci. 2018. PMID: 29688614

7

Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.

Kolarik M, Indra R, Adam V, Heger Z, Kopeckova K, Arlt VM, Stiborova M. Kolarik M, et al. Among authors: kopeckova k. Neuro Endocrinol Lett. 2019 Feb;39(7):515-524. Neuro Endocrinol Lett. 2019. PMID: 30860683

8

Nanodrugs used in cancer therapy.

Kopeckova K, Eckschlager T, Sirc J, Hobzova R, Plch J, Hrabeta J, Michalek J. Kopeckova K, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Jun;163(2):122-131. doi: 10.5507/bp.2019.010. Epub 2019 Apr 9. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019. PMID: 30967685 Free article. Review.

9

Identification of Human Enzymes Oxidizing the Anti-Thyroid-Cancer Drug Vandetanib and Explanation of the High Efficiency of Cytochrome P450 3A4 in its Oxidation.

Indra R, Pompach P, Martínek V, Takácsová P, Vavrová K, Heger Z, Adam V, Eckschlager T, Kopečková K, Arlt VM, Stiborová M. Indra R, et al. Among authors: kopeckova k. Int J Mol Sci. 2019 Jul 10;20(14):3392. doi: 10.3390/ijms20143392. Int J Mol Sci. 2019. PMID: 31295928 Free PMC article.

10

Role of Genetic Variation in Cytochromes P450 in Breast Cancer Prognosis and Therapy Response.

Hlaváč V, Václavíková R, Brynychová V, Ostašov P, Koževnikovová R, Kopečková K, Vrána D, Gatěk J, Souček P. Hlaváč V, et al. Among authors: kopeckova k. Int J Mol Sci. 2021 Mar 10;22(6):2826. doi: 10.3390/ijms22062826. Int J Mol Sci. 2021. PMID: 33802237 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

56 results

Search Page